BioMark Diagnostics, Inc.

Recent News

  • The US Patent Office Grants BioMark Additional Patent for Its Liquid Biopsy Technology

    Vancouver, British Columbia--(Newsfile Corp. - September 20, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that the US Patent Office (USPTO) has granted BioMark patent number US 11,447,168 that covers a novel approach to diagnosing and measuring treatment response for various forms of hard to detect and treat cancer. The technology can also be...

    2022-09-20 8:30 AM EDT
  • BioMark to Present Validation Data of Its Multianalyte Metabolite Panel for Lung Cancer Screening at the ESMO Congress 2022

    Vancouver, British Columbia--(Newsfile Corp. - September 8, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it's abstract titled "Metabolomic Profiling for the Early Detection of Lung Cancer" has been accepted for presentation at the upcoming ESMO Congress 2022 taking place on September 9 – 13, 2022 in Paris, France.The Company will be presenting...

    2022-09-08 8:30 AM EDT
  • BioMark Selected by the Medical Alley and Investissement Quebec to Join the Us Go-To-Market Accelerator

    Vancouver, British Columbia--(Newsfile Corp. - September 1, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an oncology-focused company with advanced near-to-market liquid biopsy diagnostic technologies is pleased to announce today that its Quebec-based wholly-owned subsidiary BioMark Diagnostic Solutions Inc. ("BDS") have been selected among the top 10 innovative companies to participate in the 2022 MedTech & Digital Health U.S. Market Access Program for Quebec companies with Medical Alley. The U.S. Market Access Program is a...

    2022-09-01 8:30 AM EDT
  • BioMark Provides First-Quarter 2022 Financial Results and Operational Update

    Vancouver, British Columbia--(Newsfile Corp. - August 30, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an oncology-focused company with advanced near-to-market liquid biopsy diagnostic technologies announced today its financial results and operational update for the quarter ended June 30, 2022."We closed out the quarter with great milestone accomplishment that reflect the ongoing momentum we have built towards our commercialization efforts for our blood-based assay designed for early detection and screening of lung...

    2022-08-30 8:30 AM EDT
  • BioMark Provides Financial Results for the Year Ended March 31, 2022, and Recent Corporate Highlights

    Vancouver, British Columbia--(Newsfile Corp. - July 14, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an oncology-focused company with advanced near-to-market liquid biopsy diagnostic technologies is pleased to announce today its financial results and recent corporate highlights for the full-year ended March 31, 2022 "We closed out the year with great milestone accomplishment that reflects the ongoing momentum we have built toward our goal to commercialize our blood-based assay for the early...

    2022-07-14 8:30 AM EDT
  • BioMark Continues to Strengthen Its Intellectual Property Position with New Patent and Trademark Use in Canada

    Vancouver, British Columbia--(Newsfile Corp. - June 21, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company developing molecular diagnostic tests with a focus on hard to detect and treat cancers, is pleased to announce today that it has been successful in obtaining a novel patent in Japan, No. 7038044, further strengthening the Company's intellectual property position worldwide and coverage of its blood-based technology for early lung...

    2022-06-21 8:30 AM EDT
  • BioMark Diagnostics and the Icahn School of Medicine at Mount Sinai Announce Partnership to Advance Early Lung Cancer Screening Technology

    Vancouver, British Columbia--(Newsfile Corp. - June 7, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, is pleased to announce today that BioMark and the Icahn School of Medicine at Mount Sinai in New York ("Icahn Mount Sinai") have entered into collaborative research agreement to work together on clinical studies related to early lung cancer diagnosis for...

    2022-06-07 8:30 AM EDT
  • BioMark Announces Closing of $1,5 Million Financing Round to Accelerate Commercialization of Its Liquid Biopsy Technology

    Vancouver, British Columbia--(Newsfile Corp. - May 4, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it has closed a financing round to accelerate the commercialization of its liquid biopsy technology.The financing round included a non-brokered private placement for gross proceeds of $1,265,500 wherein BioMark issued 5,062,000 units at a price...

    2022-05-04 8:30 AM EDT